↓ Skip to main content

Oncotarget

Article Metrics

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

Overview of attention for article published in Oncotarget, November 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
1 news outlet
patent
8 patents

Citations

dimensions_citation
126 Dimensions

Readers on

mendeley
94 Mendeley
Title
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
Published in
Oncotarget, November 2013
DOI 10.18632/oncotarget.1572
Pubmed ID
Authors

Anastasia Wyce, Yan Degenhardt, Yuchen Bai, BaoChau Le, Susan Korenchuk, Ming-Chih Crouthamel, Charles F. McHugh, Robert Vessella, Caretha L. Creasy, Peter J. Tummino, Olena Barbash

Abstract

BET (bromodomain and extra-terminal) proteins regulate gene expression through their ability to bind to acetylated chromatin and subsequently activate RNA PolII-driven transcriptional elongation. Small molecule BET inhibitors prevent binding of BET proteins to acetylated histones and inhibit transcriptional activation of BET target genes. BET inhibitors attenuate cell growth and survival in several hematologic cancer models, partially through the down-regulation of the critical oncogene, MYC. We hypothesized that BET inhibitors will regulate MYC expression in solid tumors that frequently over-express MYC. Here we describe the effects of the highly specific BET inhibitor, I-BET762, on MYC expression in prostate cancer models. I-BET762 potently reduced MYC expression in prostate cancer cell lines and a patient-derived tumor model with subsequent inhibition of cell growth and reduction of tumor burden in vivo. Our data suggests that I-BET762 effects are partially driven by MYC down-regulation and underlines the critical importance of additional mechanisms of I-BET762 induced phenotypes.

Mendeley readers

The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Denmark 1 1%
Unknown 92 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 26 28%
Student > Master 15 16%
Student > Ph. D. Student 14 15%
Student > Bachelor 10 11%
Student > Doctoral Student 4 4%
Other 15 16%
Unknown 10 11%
Readers by discipline Count As %
Agricultural and Biological Sciences 25 27%
Biochemistry, Genetics and Molecular Biology 15 16%
Chemistry 15 16%
Medicine and Dentistry 13 14%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Other 7 7%
Unknown 14 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2020.
All research outputs
#1,837,777
of 18,881,749 outputs
Outputs from Oncotarget
#722
of 13,707 outputs
Outputs of similar age
#38,689
of 357,159 outputs
Outputs of similar age from Oncotarget
#15
of 714 outputs
Altmetric has tracked 18,881,749 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,707 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 357,159 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 714 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.